 Brandon Mcmahon
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombosis | 5 | 2015 | 295 | 1.390 |
Why?
| | Myeloproliferative Disorders | 8 | 2022 | 26 | 1.320 |
Why?
| | Urokinase-Type Plasminogen Activator | 4 | 2015 | 28 | 1.060 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2015 | 75 | 0.960 |
Why?
| | Neoplasms | 8 | 2020 | 2086 | 0.940 |
Why?
| | Thrombocytopenia | 3 | 2016 | 177 | 0.930 |
Why?
| | Hemorrhage | 5 | 2018 | 600 | 0.890 |
Why?
| | Anticoagulants | 4 | 2018 | 547 | 0.880 |
Why?
| | Plasminogen | 3 | 2013 | 29 | 0.750 |
Why?
| | Fibrinolysin | 2 | 2013 | 11 | 0.740 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 2 | 2015 | 10 | 0.560 |
Why?
| | Anemia, Pernicious | 1 | 2016 | 9 | 0.530 |
Why?
| | Pancytopenia | 1 | 2016 | 7 | 0.520 |
Why?
| | Neoplasm Proteins | 2 | 2009 | 385 | 0.510 |
Why?
| | Hypothyroidism | 1 | 2016 | 65 | 0.510 |
Why?
| | Myelodysplastic Syndromes | 2 | 2016 | 119 | 0.490 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 44 | 0.450 |
Why?
| | Heparin | 1 | 2014 | 225 | 0.420 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 12 | 0.420 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 227 | 0.410 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 787 | 0.400 |
Why?
| | Thrombophilia | 2 | 2009 | 61 | 0.380 |
Why?
| | Blood Platelets | 1 | 2014 | 326 | 0.380 |
Why?
| | Polycythemia Vera | 4 | 2022 | 12 | 0.370 |
Why?
| | Fibrinolysis | 2 | 2009 | 126 | 0.360 |
Why?
| | Medical Oncology | 4 | 2022 | 229 | 0.340 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1032 | 0.340 |
Why?
| | Interferon Type I | 3 | 2015 | 128 | 0.310 |
Why?
| | Tissue Plasminogen Activator | 2 | 2009 | 204 | 0.300 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 1875 | 0.290 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2015 | 388 | 0.280 |
Why?
| | Primary Myelofibrosis | 2 | 2022 | 9 | 0.230 |
Why?
| | Thrombocythemia, Essential | 1 | 2022 | 6 | 0.210 |
Why?
| | Interferon-alpha | 2 | 2014 | 185 | 0.200 |
Why?
| | Humans | 31 | 2022 | 114043 | 0.200 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 271 | 0.200 |
Why?
| | Mastocytosis, Systemic | 1 | 2018 | 6 | 0.160 |
Why?
| | Eosinophilia | 1 | 2020 | 186 | 0.150 |
Why?
| | Chicago | 2 | 2016 | 45 | 0.150 |
Why?
| | Risk Factors | 4 | 2015 | 8614 | 0.140 |
Why?
| | Neovascularization, Pathologic | 2 | 2009 | 280 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2009 | 521 | 0.140 |
Why?
| | Janus Kinase 2 | 2 | 2015 | 31 | 0.140 |
Why?
| | Anaphylaxis | 1 | 2018 | 144 | 0.130 |
Why?
| | Philadelphia Chromosome | 1 | 2016 | 15 | 0.130 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2016 | 74 | 0.130 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2016 | 53 | 0.120 |
Why?
| | Age Factors | 4 | 2015 | 2885 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 60 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2016 | 115 | 0.120 |
Why?
| | Thienamycins | 1 | 2015 | 4 | 0.120 |
Why?
| | Biomarkers | 2 | 2016 | 3397 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 230 | 0.120 |
Why?
| | Piperacillin | 1 | 2015 | 8 | 0.120 |
Why?
| | Inactivation, Metabolic | 1 | 2015 | 11 | 0.120 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 18 | 0.120 |
Why?
| | Vitamin K | 1 | 2015 | 42 | 0.120 |
Why?
| | Cell Movement | 2 | 2009 | 863 | 0.120 |
Why?
| | Signal Transduction | 4 | 2016 | 4501 | 0.120 |
Why?
| | False Positive Reactions | 1 | 2014 | 109 | 0.120 |
Why?
| | Hemostasis | 1 | 2014 | 64 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 517 | 0.110 |
Why?
| | Pyrazoles | 2 | 2016 | 361 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2015 | 184 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 83 | 0.110 |
Why?
| | Blood Transfusion | 1 | 2016 | 265 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2016 | 405 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2015 | 184 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 492 | 0.110 |
Why?
| | Thrombocytosis | 1 | 2012 | 6 | 0.110 |
Why?
| | Interferon-beta | 1 | 2013 | 79 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1791 | 0.100 |
Why?
| | Leukocytosis | 1 | 2012 | 34 | 0.100 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2012 | 23 | 0.100 |
Why?
| | Prognosis | 3 | 2016 | 3315 | 0.100 |
Why?
| | Administration, Oral | 1 | 2015 | 725 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 365 | 0.100 |
Why?
| | Adult | 8 | 2022 | 30375 | 0.100 |
Why?
| | Annexin A2 | 2 | 2009 | 10 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 813 | 0.100 |
Why?
| | Nitriles | 1 | 2012 | 149 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1142 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 344 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 319 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 293 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 533 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2014 | 591 | 0.090 |
Why?
| | Apoptosis | 2 | 2009 | 2349 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2014 | 694 | 0.080 |
Why?
| | Pyrimidines | 1 | 2012 | 374 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2371 | 0.080 |
Why?
| | Mutation | 3 | 2018 | 3338 | 0.080 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2009 | 12 | 0.080 |
Why?
| | Cryoglobulins | 1 | 2009 | 6 | 0.080 |
Why?
| | Carboxypeptidase B2 | 1 | 2009 | 3 | 0.080 |
Why?
| | Plasminogen Inactivators | 1 | 2009 | 3 | 0.080 |
Why?
| | Receptors, Peptide | 1 | 2009 | 15 | 0.080 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2009 | 11 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 14 | 0.080 |
Why?
| | Cerebral Infarction | 1 | 2009 | 39 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2012 | 527 | 0.080 |
Why?
| | Factor VII | 1 | 2008 | 24 | 0.080 |
Why?
| | Edetic Acid | 1 | 2008 | 47 | 0.080 |
Why?
| | Factor VIII | 1 | 2008 | 52 | 0.080 |
Why?
| | von Willebrand Factor | 1 | 2008 | 55 | 0.080 |
Why?
| | Time Factors | 2 | 2018 | 6077 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 116 | 0.080 |
Why?
| | Animals | 7 | 2016 | 31565 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1310 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 176 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1175 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 245 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 438 | 0.070 |
Why?
| | Blood Coagulation Disorders | 1 | 2009 | 154 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 347 | 0.070 |
Why?
| | Cell Division | 1 | 2009 | 754 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2012 | 1016 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2016 | 12521 | 0.070 |
Why?
| | Cytokines | 2 | 2014 | 1824 | 0.060 |
Why?
| | Ischemia | 1 | 2009 | 361 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1471 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 325 | 0.060 |
Why?
| | Female | 7 | 2016 | 59325 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2015 | 955 | 0.060 |
Why?
| | Mice | 5 | 2014 | 14841 | 0.060 |
Why?
| | Societies, Medical | 2 | 2018 | 655 | 0.060 |
Why?
| | Aged | 4 | 2016 | 18969 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 641 | 0.060 |
Why?
| | Aging | 1 | 2014 | 1611 | 0.060 |
Why?
| | Janus Kinases | 2 | 2016 | 12 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 347 | 0.060 |
Why?
| | Erythroid Cells | 2 | 2015 | 7 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2018 | 9049 | 0.060 |
Why?
| | Middle Aged | 5 | 2016 | 26605 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 249 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1257 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1206 | 0.050 |
Why?
| | Autoantibodies | 1 | 2009 | 1347 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1117 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 2 | 2014 | 338 | 0.040 |
Why?
| | Male | 6 | 2016 | 55396 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1558 | 0.040 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 26 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.040 |
Why?
| | Fibroblasts | 2 | 2014 | 834 | 0.040 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 40 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2018 | 63 | 0.040 |
Why?
| | Prevalence | 2 | 2015 | 2247 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 2698 | 0.040 |
Why?
| | Mast Cells | 1 | 2018 | 116 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 274 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 377 | 0.040 |
Why?
| | Bone Marrow | 1 | 2018 | 243 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2015 | 3861 | 0.030 |
Why?
| | Receptors, Thrombopoietin | 1 | 2016 | 5 | 0.030 |
Why?
| | Thrombopoietin | 1 | 2016 | 4 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 714 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 27 | 0.030 |
Why?
| | Benzoates | 1 | 2016 | 38 | 0.030 |
Why?
| | Receptors, Fc | 1 | 2016 | 45 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 80 | 0.030 |
Why?
| | General Practice | 1 | 2016 | 27 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 949 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 79 | 0.030 |
Why?
| | Autophagy-Related Protein-1 Homolog | 1 | 2015 | 6 | 0.030 |
Why?
| | Azacitidine | 1 | 2016 | 129 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1024 | 0.030 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 6306 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 629 | 0.030 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 31 | 0.030 |
Why?
| | Interferons | 1 | 2016 | 151 | 0.030 |
Why?
| | Response Elements | 1 | 2015 | 82 | 0.030 |
Why?
| | Nuclear Cap-Binding Protein Complex | 1 | 2014 | 1 | 0.030 |
Why?
| | Ubiquitins | 1 | 2014 | 31 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 13 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1836 | 0.030 |
Why?
| | Guanosine | 1 | 2014 | 39 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2014 | 28 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 541 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 531 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 107 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 300 | 0.030 |
Why?
| | Risk | 1 | 2016 | 810 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 613 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 294 | 0.030 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2013 | 27 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 519 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1204 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2013 | 133 | 0.030 |
Why?
| | Aspirin | 1 | 2015 | 324 | 0.030 |
Why?
| | Hospitalists | 1 | 2016 | 172 | 0.030 |
Why?
| | U937 Cells | 1 | 2012 | 22 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 301 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1422 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 213 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 517 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2013 | 122 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1829 | 0.020 |
Why?
| | Leukemia | 1 | 2013 | 208 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 784 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 233 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 367 | 0.020 |
Why?
| | Splanchnic Circulation | 1 | 2009 | 10 | 0.020 |
Why?
| | Infarction | 1 | 2009 | 12 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2009 | 21 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 31 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 175 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 82 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2958 | 0.020 |
Why?
| | Giant Cell Arteritis | 1 | 2009 | 48 | 0.020 |
Why?
| | Immunoassay | 1 | 2008 | 95 | 0.020 |
Why?
| | Tretinoin | 1 | 2009 | 122 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 281 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 148 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1356 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 1762 | 0.020 |
Why?
| | Plasma | 1 | 2008 | 181 | 0.020 |
Why?
| | Spleen | 1 | 2009 | 485 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 920 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 2562 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1695 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4402 | 0.020 |
Why?
| | United States | 1 | 2018 | 12137 | 0.010 |
Why?
| | Kidney | 1 | 2009 | 1182 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1633 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 17800 | 0.010 |
Why?
|
|
Mcmahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|